Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Colorcon
Mallinckrodt
Moodys
Boehringer Ingelheim

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

CAVERJECT Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Caverject, and when can generic versions of Caverject launch?

Caverject is a drug marketed by Pfizer and Pharmacia And Upjohn and is included in three NDAs.

The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

Drug patent expirations by year for CAVERJECT
Drug Prices for CAVERJECT

See drug prices for CAVERJECT

Synonyms for CAVERJECT
(-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate
(-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid
(-)-Protaglandin E1
(+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate
(+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid
(11?,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid
(11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid
(13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid
(1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
11,15-Dihydroxy-9-oxoprost-13-en-1-oate
11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (ACD/Name 4.0)
119314-69-1
11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid
22299-37-2
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
50-83-9
50865-30-0
7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid
7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
7-[(1r,3r)-3-Hydroxy-2-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-5-Oxocyclopentyl]heptanoic Acid
7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]hepta noic acid
745-65-3
745P653
9-oxo-11R,15S-dihydroxy-13E-prostaenoic acid
AB0014134
AB00514004
AB00514004_09
AB00514004-06
AB00514004-08
AB2000131
AC-6095
AC1NQXHQ
AI3-62116
AKOS015961103
Alista
alprostadil
Alprostadil (JP17/USP/INN)
Alprostadil [USAN:USP:INN:BAN:JAN]
Alprostadil Prostoglandin E1
Alprostadil, European Pharmacopoeia (EP) Reference Standard
Alprostadil, meets USP testing specifications
Alprostadil, United States Pharmacopeia (USP) Reference Standard
Alprostadil(Caverject)
Alprostadil(usan)
Alprostadilum
Alprostadilum [INN-Latin]
Alprox-TD
AS-16360
B2154
BC205461
BCP01740
BCP9000277
BDBM50101853
Befar
Befar (TN)
BG0025
BIDD:GT0747
BML1-F06
BPBio1_001293
BRD-K52459643-001-06-0
BRD-K52459643-001-10-2
BRD-K52459643-001-17-7
BSPBio_001175
BSPBio_001488
C04741
CAS-745-65-3
Caverject Impulse
CCG-101188
CHEBI:15544
CHEMBL495
CPD000112594
CS-1905
Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-
Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l-
D00180
DSSTox_CID_2578
DSSTox_GSID_22578
DSSTox_RID_76640
DTXSID9022578
Edex
EINECS 212-017-2
EX-A1411
F5TD010360
FemLife
Femprox
GMVPRGQOIOIIMI-DWKJAMRDSA-N
GTPL1882
HEI-507
HMS1361K10
HMS1571K17
HMS1791K10
HMS1989K10
HMS2052L11
HMS2090L08
HMS2098K17
HMS3268I09
HMS3402K10
HMS3648O17
HMS3715K17
HY-B0131
IDI1_033958
K274
l-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
l-PGE1
l-Prostaglandin E1
Lipoprost
Liprostin
LMFA03010134
MFCD00077860
Minprog
MLS000758964
MLS001424250
MolPort-003-939-183
MR 256
MR-256
Muse
NC00438
NCGC00016535-01
NCGC00025234-02
NCGC00025234-03
NCGC00025234-04
NCGC00025234-05
NSC 165559
ONO 1608
PGE-1
PGE1
PGE1 Oligomer
PGE1, Prostaglandin E1, powder
PGE1;Prostaglandin E1
PGE1alpha
Prestwick2_001018
Prestwick3_001018
Prink
Prink (TN)
Promostan
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer
Prostaglandin E1
Prostaglandin E1, >=98% (HPLC), synthetic
Prostaglandin E1, >=99.0% (TLC)
Prostaglandin E1, 98+%
Prostaglandin E1, powder, gamma-irradiated, BioXtra, suitable for cell culture
Prostaglandin E1, synthetic, powder, BioReagent, suitable for cell culture
Prostaglandin E1; PGE1
Prostaglandin E1;Edex;Muse;Liprostin;Caverject
Prostaglandin-E1
Prostaglandine E
Prostandin
Prostavasin
Prostin VR
Prostin VR Pediatric
Prostin VR pediatric (TN)
Prostivas
RayVa
RP17688
s1508
SAM001246840
SAM001246845
SAM001247093
SCHEMBL33317
SMP2_000271
SMR000112594
SR-01000597593
SR-01000597593-1
SR-01000597593-5
SR-01000597593-6
SR-01000946253
SR-01000946253-1
ST50826271
Sugiran
SYN3025
Topiglan
Tox21_110482
U 10136
U-10,136
U-10136
UNII-F5TD010360
Vasaprostan
Viridal
Vitaros
Vitaros (TN)
W-104416
XPG
ZINC3813088

US Patents and Regulatory Information for CAVERJECT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CAVERJECT alprostadil INJECTABLE;INJECTION 020755-001 Oct 31, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-004 May 19, 1997 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-003 Jun 27, 1996 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CAVERJECT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-003 Jun 27, 1996   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995   Start Trial   Start Trial
Pharmacia And Upjohn CAVERJECT alprostadil INJECTABLE;INJECTION 020379-002 Jul 6, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Colorcon
Baxter
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.